222
Participants
Start Date
December 1, 2021
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2027
Tarlatamab
Intravenous (IV) infusion
Hopitaux Universitaires de Geneve, Geneva
Rigshospitalet, Copenhagen
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven
Universitaetsklinikum Krems, Krems
Landeskrankenhaus Salzburg, Salzburg
Grand Hopital de Charleroi - Site Saint Joseph, Gilly
Universitair Ziekenhuis Gent, Ghent
National Cancer Center, Goyang-si Gyeonggi-do
Taipei Veterans General Hospital, Taipei
Henry Dunant Hospital Center, Athens
Sotiria General Hospital, Athens
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do
Centre Hospitalier Universitaire Nord, Marseille
University of Pittsburgh Medical Center Cancer Pavillion, Pittsburgh
Metropolitan Hospital, Athens
Christiana Care Health Services, Newark
Azienda Socio Sanitaria Territoriale dei Sette Laghi Ospedale di Circolo e Fondazione Macchi, Varese
LungenClinic Grosshansdorf GmbH, Großhansdorf
General Hospital of Patras Agios Andreas, Pátrai
West Virginia University Health Sciences Center, Morgantown
Wake Forest Baptist Comprehensive Cancer Research Center, Winston-Salem
Duke University Medical Center, Durham
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda
Hospital Regional Universitario de Malaga, Málaga
Winship Cancer Institute, Atlanta
Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse
Moffitt Cancer Center, Tampa
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou, Rennes
University of Alabama at Birmingham, Birmingham
Sarah Cannon Research Institute, Nashville
Azienda Ospedaliero-Universitaria di Parma, Parma
University Hospitals Cleveland Medical Center, Cleveland
Oncology Hematology Care Inc, Cincinnati
Hospital Universitari i Politecnic La Fe, Valencia
Henry Ford Health System, Detroit
Universitaetsklinikum Koeln, Cologne
University of Iowa, Iowa City
Theagenion Cancer Hospital, Thessaloniki
Euromedica General Clinic of Thessaloniki, Thessaloniki
Agios Loukas Clinic, Thessaloniki
Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil, Strasbourg
Centre Hospitalier Lyon Sud, Pierre-Bénite
University Hospital of Heraklion, Heraklion - Crete
University of Arkansas for Medical Sciences, Little Rock
Institut Curie, Paris
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
Institut Gustave Roussy, Villejuif
Universitaetsklinikum Wuerzburg, Würzburg
National Cancer Centre Singapore, Singapore
Dana Farber - Harvard Cancer Center, Boston
Dartmouth Hitchcock Medical Center, Hanover
Istituti Fisioterapici Ospitalieri Regina Elena San Gallicano, Rome
Aichi Cancer Center, Nagoya
National Cancer Center Hospital East, Kashiwa-shi
Okayama University Hospital, Okayama
Kindai University Hospital, Osakasayama-shi
Shizuoka Cancer Center, Sunto-gun
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku
Wakayama Medical University Hospital, Wakayama
Leids Universitair Medisch Centrum, Leiden
Erasmus Medisch Centrum, Rotterdam
Uniwersyteckie Centrum Kliniczne, Gdansk
Centra Medyczne Medyceusz Sp zoo, Lodz
Mazowieckie centrum leczenia, Otwock
Hospital da Luz, SA, Lisbon
Hospital CUF Descobertas, Lisbon
Centro Hospitalar Universitario do Porto EPE - Hospital de Santo Antonio, Porto
Hospital Cuf porto, Porto
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto
Yonsei University Health System Severance Hospital, Seoul
Asan Medical Center, Seoul
Samsung medical center, Seoul
The Catholic University of Korea Seoul St Marys Hospital, Seoul
Hospital Universitari Vall d Hebron, Barcelona
Hospital Clinic i Provincial de Barcelona, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Instituto Catalan de Oncologia Hospital Duran i Reynals, L'Hospitalet de Llobregat
Sarah Cannon Research Institute UK, London
Christie Hospital, Manchester
Lead Sponsor
Amgen
INDUSTRY